2018-06-09
作者:杨学宁
近年来,免疫治疗在肿瘤综合治疗体系中不断发展,其相对于传统的放疗及化疗具有特异性强、有效率高、无放化疗的毒副作用、病人耐受性好等优点的同时,仍具有疗程长、见效慢,甚至出现“假性进展”(pseudoprogression)现象(也可以称为闪光现象)等缺点;因而多位学者和多个组织利用现有的肿瘤治疗疗效评价体系(WHO标准、RECIST1.0、RECIST1.1等)探讨评价免疫治疗的合理性和准确性。
欧洲癌症研究和治疗组织(EORTC,European organization for Research and Treatment of Cancer)的RECIST working group(http://www.eortc.org/recist/) 在RECIST1.1版的基础上,结合近年来实体瘤免疫治疗的经验,2017年3月在LANCET发布了用于评价免疫治疗疗效的修订版RECIST 1.1(modified RECIST 1.1 for immune-based therapeutics,简称iRECIST)
用于评价免疫治疗疗效的修订版RECIST 1.1(modified RECIST 1.1 for immune-based therapeutics,简称iRECIST)已发布。但新标准需要练习才能熟练应用,本文收集了已有的资料以供参考。
iRECIST专业名词和缩写
•“i”指iRECIST
•RECIST=实体瘤反应评价标准Response Evaluation Criteria in Solid Tumours.
•iBOR=最佳总疗效best overall response.
•iCR=完全缓解complete response.
•iPR=部分缓解partial response.
•iSD=疾病稳定stable disease.
•NE=不能评价not evaluable.
•iUPD=未确认进展unconfirmed progression.
•iCPD=确认进展confirmed progression.
•iSD=疾病稳定stable disease.
•non-iCR/non-iUPD=完全缓解或者部分缓解的标准均未能达到.
•NL=新病灶 new lesion
iRECIST专业名词和缩写
“i”指iRECIST
RECIST=实体瘤反应评价标准Response Evaluation Criteria in Solid Tumours.
iBOR=最佳总疗效best overall response.
iCR=完全缓解complete response.
iPR=部分缓解partial response.
iSD=疾病稳定stable disease.
NE=不能评价not evaluable.
iUPD=未确认进展unconfirmed progression.
iCPD=确认进展confirmed progression.
iSD=疾病稳定stable disease.
non-iCR/non-iUPD=完全缓解或者部分缓解的标准均未能达到.
NL=新病灶 new lesion
【参考文献】
1. Seymour L, Bogaerts J, Perrone A, et al; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.Lancet Oncol. 2017 Mar;18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2.
推荐阅读
文章评论
注册或登后即可发表评论
登录/注册
全部评论(0)